Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Omfurn India FPO Date, Review, Price, Allotment Details

By Jagat Joshi
March 26, 2024

Omfurn India FPO Details: Omfurn India FPO date is fixed, The FPO will open on March 20 and will close on March 22. Omfurn India is a NSE SME FPO to raise ₹27 crores via FPO. The Omfurn India FPO price band is fixed at ₹71 to ₹75 with a market lot of 2400 shares.

Omfurn India Limited is a manufacturer and supplier of Pre-Finished Wooden Doors and Modular Furniture in India. They have been in business since November 13, 1997, which gives them a quarter-century of experience in this industry. Since then, they have been reaching remarkable milestones in creation and innovation. They create a wide range of wooden doors and furniture for Modular Kitchens, Wardrobes, Vanities, and Modern Office furniture through customized, system-based, or turnkey projects PAN India, was listed in NSE in the year 2017.

Their Team consists of professionals specialized in their respective fields. A team of technical administrative, project personnel, and engineers work in conjunction with architects, interior designers, management staff, etc., to offer the best accomplished furnished products. They are deeply committed to their duty to nature and their planet Earth. They believe in providing environmentally sustainable products to protect their heritage for future generations. For this purpose, they are Green Building Certified and have completed Greenfield Projects in India.

Omfurn India maintains their quality standards and has obtained certifications like ISO 9001, 14001, and 45001 under the strict certification rules. They believe their infrastructure is designed to manufacture high-quality furniture products efficiently and effectively. Their in-house manufacturing factory in Umbergaon spans a total area of 1,61,460 sq. ft..

Objects of the Issue:

Funding capital expenditure towards installation of plant & machinery in our existing premises along with required civil, electric and fabrication work.
Repayment/prepayment, in full or part, of certain borrowings availed of by the Company.
Funding to meet working capital requirements.
General corporate purposes.

Omfurn India FPO Review

May Apply

Omfurn India FPO Date & Price Band Details

FPO Open:	March 20, 2024
FPO Close:	March 22, 2024
FPO Size:	Approx ₹27 Crores, 3,600,000 Equity Shares
Face Value:	₹10 Per Equity Share
FPO Price Band:	₹71 to ₹75 Per Equity Share
FPO Listing on:	NSE SME
Retail Quota:	35% of the net offer
QIB Quota:	50% of the net offer
NII Quota:	15% of the net offer
DRHP Draft Prospectus:	Click Here
RHP Draft Prospectus:	Click Here
Anchor Investors in FPO:	Click Here

Omfurn India FPO Market Lot

The Omfurn India FPO minimum market lot is 2400 shares with a ₹180,000 application amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	2400	₹180,000
Retail Maximum	1	2400	₹180,000
S-HNI Minimum	2	4800	₹360,000

Omfurn India FPO Dates

The Omfurn India FPO date is March 20 and the FPO close date is March 22. The FPO allotment date is March 26 and the FPO might list on March 28.

FPO Open Date:	March 20, 2024
FPO Close Date:	March 22, 2024
Basis of Allotment:	March 26, 2024
Refunds:	March 27, 2024
Credit to Demat Account:	March 27, 2024
FPO Listing Date:	March 28, 2024

You can check FPO subscription status and FPO allotment status on their respective pages.

Omfurn India FPO Form

How to apply Omfurn India FPO? You can apply Omfurn India FPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the Omfurn India FPO in the Invest section. The other option you can apply Omfurn India FPO via FPO forms download via the NSE website. Check out the Omfurn India forms – click NSE FPO Forms download, fill and submit in your bank or with your broker.

Omfurn India Company Financial Report

₹ in Crores
Year	Revenue	Expense	PAT
2021	₹21.85	₹22.91	₹0.99
2022	₹32.30	₹31.65	₹0.60
2023	₹71.08	₹65.96	₹4.15
2023 6M	₹44.75	₹40.70	₹2.89

Omfurn India FPO Valuation – FY2023

Check Omfurn India FPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):	₹5.08 per Equity Share
Price/Earning P/E Ratio:	13.99
Return on Net Worth (RoNW):	16.12%
Net Asset Value (NAV):	₹31.49 per Equity Share

Peer Group

Company Promoters

Mr. Rajendra Chitbahal Vishwakarma
Mr. Mahendra Chitbahal Vishwakarma
Mr. Narendra Chitbahal Vishwakarma
Mr. Prashant Rajendra Vishwakarma
Mr. Parmanand Mahendra Vishwakarma

Omfurn India FPO Registrar

Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: FPO@bigshareonline.com
Website: http://www.bigshareonline.com

Omfurn India FPO Allotment Status

Check Omfurn India FPO allotment status on Bigshare website URL. Click Here

Omfurn India FPO Lead Managers aka Merchant Bankers

Gretex Corporate Services Limited

Company Address

Omfurn India
109, Gundecha Industrial Complex,
Akrurali Road, Kandivali (East),
Mumbai – 400101, Maharashtra, India
Phone: +91-2242108900
Email: omfurn@omfurnindia.com
Website: https://www.omfurnindia.com/

Omfurn India FPO FAQs

What is Omfurn India FPO?

Omfurn India FPO is an NSE SME FPO. They are going to raise ₹27 Crores via FPO. The issue is priced at ₹71 to ₹75 per equity share. The FPO is to be listed on NSE.

When Omfurn India FPO will open?

The FPO is to open on March 20, 2024 for QIB, NII, and Retail Investors.

What is Omfurn India FPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Omfurn India FPO?

You can apply Omfurn India FPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the Omfurn India FPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on FPO. You will see the FPO Name “Omfurn India”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit FPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the Omfurn India FPO through Upstox?

Log in to Upstox Application with your credentials. Select the FPO. You will see the FPO Name “Omfurn India”. Click on Bid Button. Confirm your application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the Omfurn India FPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the FPO. You will see the FPO Name “Omfurn India”. Click on Bid Button. Confirm your application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is Omfurn India FPO Size?

Omfurn India FPO size is ₹27 crores.

What is Omfurn India FPO Price Band?

Omfurn India FPO Price Band is ₹71 to ₹75 per equity share.

What is Omfurn India FPO Minimum and Maximum Lot Size?

The FPO bid is 2400 shares with ₹180,000.

What is Omfurn India FPO Allotment Date?

Omfurn India FPO allotment date is March 28, 2024.

What is Omfurn India FPO Listing Date?

Omfurn India FPO listing date is March 28, 2024. The FPO to list on NSE SME.

Note: The Omfurn India FPO details are announced officially. The FPO grey market premium ( Omfurn India FPO Premium) is updated on the respective page. You can check our IPO grey market page for daily updates.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.